Provectus Biopharmaceuticals, Inc. · OTC:PVCT
Provectus Biopharmaceuticals — Shareholder Meeting (June 2025)
19 slides from Provectus Biopharmaceuticals's shareholder meeting presentation, Jun 18, 2025
Slide 1: 2025 Annual Stockholder Meeting
2025 ANNUAL STOCKHOLDER MEETING Copyright © 2025 Provectus Biopharmaceuticals, Inc. re provectus OTCQB: PVCT biopharmaceuticals
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS The information in this presentation may include “forward- looking statements” within the meaning of U.S. federal securities legislation and relating to the business of Provectus Biopharmaceuticals, Inc. and its affiliates (Provectus or the Company) that are based on the o
Slide 3: 2024 Annual Stockholder Meeting Agenda
2024 ANNUAL STOCKHOLDER MEETING AGENDA oS Part 1: Meeting Activities Part 2: Company Update 1. Welcome A. Opening Remarks & lateness B. Presentation, Rose Bengal Sodium: Systems-Aware Medicines 3. Preliminary Matters C. Q&A Session 4. Order of Business D. Closing Comments 5. Other Business 6. Report
Slide 4: Part I: Stockholder Meeting Activities
PART I: STOCKHOLDER MEETING ACTIVITIES O provectus biopharmaceuticals
Slide 5: Meeting Activities
MEETING ACTIVITIES 4. Welcome 2. Introductions 3. Preliminary Matters @ Inspector of the Election Record Date ‘© Shares Entitled to Notice and Vote © Quorum . Reading of the Notice of the Annual Meeting, Affidavit of Mailing, and Minutes ‘* Stockholders’ Proxies '* Stockholders’ Ballots 4. Order of
Slide 6: Part II
PART II: COMPANY UPDATE O provectus biopharmaceuticals
Slide 7: Opening Remarks
OPENING REMARKS ED PERSHING, CPA, CHAIRMAN & CHIEF EXECUTIVE OFFICER O provectus biopharmaceuticals
Slide 8: Presentation: Rose Bengal Sodium: Systems-Aware Medicines
PRESENTATION ROSE BENGAL SODIUM: SYSTEMS-AWARE MEDICINES DOMINIC RODRIGUES, VICE CHAIRMAN & PRESIDENT O provectus biopharmaceuticals
Slide 9: The Rose Bengal Sodium (RBS) Molecule
THE ROSE BENGAL SODIUM (RBS) MOLECULE A Singularly Distinctive Molecule
Slide 10: Clinical-Stage Intratumoral PV-10 Injectable Solid Tumor Cancers
CLINICAL-STAGE INTRATUMORAL PV-10 INJECTABLE SOLID TUMOR CANCERS Co-lead indication: Pre-operative penile squamous cell carcinoma (penile SCC) Single agent: Intratumoral PV-10 ¢ Rationale 1. In-transit melanoma history & experience 2. Pharma business development experiences 3. TGA experience 4. Sing
Slide 11: AI-Assisted Cancer Review
AIl-ASSISTED CANCER REVIEW oS Hypothesis ¢ Methodology ¢ Conclusion Confidence level Summary: Provectus’s pharmaceutical-grade Rose Bengal Sodium drug substance and API is best understood not as a traditional drug, but as a biological re-programmer that may potentially activate both death and defens
Slide 12: Pipeline Updates
PIPELINE UPDATES © VisiRose: Clinical-stage topical PV-305 Dermatology: Clinical-stage topical PH-10 ¢ Wound healing (preclinical research): Clinical-stage topical PH-10 # Oral PV-10 (preclinical research): Clinical-stage PV-10 © Proprietary targets oTcas: PvcT 12
Slide 13: Concluding Remarks
CONCLUDING REMARKS Systems-aware medicines ¢ The potential total addressable market for Provectus's RBS drug platform oTcas: PvcT 13
Slide 14: 2024-2025 Presentations, Publications, Patents & Other Achievements
2024-2025 PRESENTATIONS, PUBLICATIONS, PATENTS & OTHER ACHIEVEMENTS* G 1, August 2024. Awarded a patent (12,064,507) by the United States Patent and Trademark Office (USPTO) titled Composition and method for oral treatment of leukemia 2. December. Launched VisiRose, Inc. ("VisiRose"), Provectus's fi
Slide 15: Q&A Session
Q&A SESSION BOARD OF DIRECTORS WEBSTER BAILEY e JACK LACEY, MD e ED PERSHING e DOMINIC RODRIGUES O provectus biopharmaceuticals 15
Slide 16: Closing Comments
CLOSING COMMENTS. ED PERSHING, CHAIRMAN & CHIEF EXECUTIVE OFFICER O provectus biopharmaceuticals 16
Slide 17: Capital Markets Snapshot
CAPITAL MARKETS SNAPSHOT Ticker PVvCT Exchange OTCQB Sector Biotechnology Market Cap $31.02 milliont 52-Week Range $0.0450 - $0.1600" Shares Outstanding 420.28 million’ oTcas: PvcT 41. As of June 16, 2025, Mailing Address Provectus Biopharmaceuticals, Inc 800 S. Gay St., Suite 1610 Knoxville, TN 379
Slide 18: Why Invest in Provectus
WHY INVEST IN PROVECTUS ea Committed to developing safe, Corporate principles of cure, accessibility, effective, accessible accountability, and affordable fiscal responsibility, immunotherapy drugs and for those afflicted with shareholder value cancer and other diseases Clinical trials demonstrating
Slide 19: OTCQB: PVCT
OTCQB: PVCT
Provectus Biopharmaceuticals — Shareholder Meeting (June 2025) on 6ix